Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14533MR)

This product GTTS-WQ14533MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14533MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12313MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ12817MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ12836MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ11250MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ5865MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ343MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ9339MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ9093MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW